Bill > SF552

This bill requires the Iowa Department of Health and Human Services (HHS) and the Department of Administrative Services (DAS) to conduct a comprehensive review of anti-obesity medications, with a specific focus on GLP-1 agonists (a class of drugs originally developed for diabetes treatment that have shown significant weight loss potential). The review will evaluate multiple aspects of these medications, including their effectiveness in weight loss, their impact on related health conditions (comorbidities), potential cost savings from reducing future medical procedures and medications, and recommended eligibility requirements. The departments will examine both the short-term and long-term financial implications of potentially covering these medications under the state's medical assistance program and health insurance plans for state employees. By January 5, 2026, HHS and DAS are required to submit a detailed report to the state's general assembly, which will include their key findings, proposed eligibility criteria, and a comprehensive analysis of the potential costs associated with covering anti-obesity medications.

Health and Social Services

Health And Human Services (S)

https://www.legis.iowa.gov/legislation/BillBook?ga=91&ba=SF552